CG Oncology, Inc. Common stock (CGON)vsMerck & Company Inc (MRK)
CGON
CG Oncology, Inc. Common stock
$66.74
+3.07%
HEALTHCARE · Cap: $5.70B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1609083% more annual revenue ($65.01B vs $4.04M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
CGON
Avoid32
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGON.
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 409.2% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Altman Z-Score. Revenue growth of 409.2% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.70 — expect wider price swings.
CGON is growing revenue faster at 409.2% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 32/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking cancer therapies, with its lead product, CG0070, an innovative oncolytic virus therapy targeting non-muscle invasive bladder cancer. The company is poised to address significant unmet medical needs in oncology, underscoring its potential to improve patient outcomes and reshape treatment approaches. As CG Oncology advances through clinical trials and critical regulatory milestones, it leverages its proprietary technology platform to distinguish itself in the competitive oncology sector. This strategic emphasis on pioneering therapeutic options presents an attractive opportunity for institutional investors interested in advancements that could significantly impact cancer care.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?